Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-29

FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, enabling continued or expanded marketing under a supplemental approv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DASATINIB (Dasatinib)

Snippet

SUPPL AP for DASATINIB (DASATINIB)